Evidence map›Paper›PMID 34437590›Full record

ArticlePloS one2021

Point-of-care microvolume cytometer measures platelet counts with high accuracy from capillary blood.

William M Dickerson, Rebecca Yu, Helena U Westergren, Jonathan Paraskos, Philipp Schatz, Anna Tigerstrom, Anna Ekman, José Sánchez, Jamie Cheng, Lillian Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

William M DickersonrHEALTH, Bedford, Massachusetts, United States of America.
Rebecca YurHEALTH, Bedford, Massachusetts, United States of America.
Helena U WestergrenPrecision Medicine & Biosamples, R&D, AstraZeneca, Gothenburg, Sweden.
Jonathan ParaskosPrecision Medicine & Biosamples, R&D, AstraZeneca, Cambridge, United Kingdom.
Philipp SchatzPrecision Medicine & Biosamples, R&D, AstraZeneca, Gothenburg, Sweden.
Anna TigerstromPrecision Medicine & Biosamples, R&D, AstraZeneca, Gothenburg, Sweden.
Anna EkmanEarly Biometrics and Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
José SánchezEarly Biometrics and Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Jamie ChengrHEALTH, Bedford, Massachusetts, United States of America.
Lillian LirHEALTH, Bedford, Massachusetts, United States of America.
Eugene Y ChanrHEALTH, Bedford, Massachusetts, United States of America.ORCID 0000-0003-1065-0050
AstraZeneca (Sweden) · SEAstraZeneca (United Kingdom) · GBDNA Medicine Institute (United States) · US

Funding

STAT Palm-Sized Blood CounterR44HL099092 · NHLBI · DNA MEDICINE INSTITUTE · PI CHAN, EUGENE YAN-HO, KELLOGG, MARK DAVID · 2012 to 2018
$4.0M
NHLBI NIH HHS R44 HL099092
6 · The paper itself

Abstract

backgroundPoint-of-care (PoC) testing of platelet count (PLT) provides real-time data for rapid decision making. The goal of this study is to evaluate the accuracy and precision of platelet counting using a new microvolume (8 μL), absolute counting, 1.5 kg cytometry-based blood analyzer, the rHEALTH ONE (rHEALTH) in comparison with the International Society of Laboratory Hematology (ISLH) platelet method, which uses a cytometer and an impedance analyzer.

methodsInclusion eligibility were healthy adults (M/F) ages 18-80 for donation of fingerprick and venous blood samples. Samples were from a random N = 31 volunteers from a single U.S. site. Samples were serially diluted to test thrombocytopenic ranges. Interfering substances and conditions were tested, including RBC fragments, platelet fragments, cholesterol, triglycerides, lipids, anti-platelet antibodies, and temperature.

resultsThe concordance between the rHEALTH and ISLH methods had a slope = 1.030 and R2 = 0.9684. The rHEALTH method showed a correlation between capillary and venous blood samples (slope = 0.9514 and R2 = 0.9684). Certain interferents changed platelet recovery: RBC fragments and anti-platelet antibodies with the ISLH method; platelet fragments and anti-platelet antibodies on the rHEALTH; and RBC fragments, platelets fragments, triglycerides and LDL on the clinical impedance analyzer. The rHEALTH's precision ranged from 3.1-8.0%, and the ISLH from 1.0-10.5%.

conclusionsThe rHEALTH method provides similar results with the reference method and good correlation between adult capillary and venous blood samples. This demonstrates the ability of the rHEALTH to provide point-of-care assessment of normal and thrombocytopenic platelet counts from fingerprick blood with high precision and limited interferences.

Indexed as

Point-of-Care SystemsAdolescentAdultAgedAged, 80 and overBiological AssayBlood Specimen CollectionCapillariesFlow CytometryHumansMicrotechnologyMiddle AgedPlatelet CountYoung Adult

Identifiers

PMID34437590
PMCPMC8389400
OpenAlexW3195898731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.